Immunotherapy markers for metastatic melanoma
Part of Cancer, Skin clinical trials.
This trial studies why immunotherapy works better for some people with advanced melanoma. It looks at markers in your blood or tissue to help doctors predict who might benefit most.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have metastatic or locally advanced melanoma that cannot be removed by surgery.
- You are getting your first treatment for this with immunotherapy alone or in combination.
- You are treated at the European Institute of Oncology in Milan between 2022 and 2027.
- You are 18 years or older.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
This study tests how well immunotherapy drugs like pembrolizumab and nivolumab work for people with advanced melanoma that has spread. It aims to find markers that predict treatment response.
This study looks at whether a simple blood test can track how well immunotherapy is working in people with advanced melanoma. It might help doctors see if the treatment is effective earlier than with scans alone.
This study looks at immune and tumor “behavior” markers in people with metastatic melanoma after standard treatment. It may help researchers understand why treatment works for some people and not others by testing blood and skin tumor samples.
This study tests a combination of three drugs (relatlimab, ipilimumab, and nivolumab) as a first treatment for advanced melanoma that cannot be removed by surgery. All participants will receive the drug combination, and the study will look at safety and how well it works.
This early trial tests CBL0137 along with ipilimumab and nivolumab (two immune-based cancer medicines) in people with stage III or possibly stage IV melanoma that can be biopsied. It may help shrink melanoma and improve immune control, while also learning how safe and effective this combination is.
Hear when a new Metastatic Melanoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.